secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001683168-26-002613
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte shareholders approve reverse stock split and increase equity plan shares by 2M at annual meeting
--------------------------------------------------------------------------------

- Approved reverse stock split at ratio 1:1.1 to 1:100; 5,067,304 for, 2,280,497 against.
- Approved amendment to 2022 Equity Incentive Plan increasing share reserve by 2,000,000 shares.
- Elected five directors (Silverman, Schechter, Abecassis, Weinstein, Walker) to hold office until 2027 annual meeting.
- Ratified CBIZ CPAs P.C. as independent auditor for FY ending April 30, 2026; 6,837,442 for votes.
- Non-binding advisory approval of executive compensation received majority support (3,306,883 for votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/0001683168-26-002613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-002613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer